Monitor The Insider Activity Of Bristol-Myers Squibb Company (BMY)


As of Thursday close, Bristol-Myers Squibb Company’s (NYSE:BMY) stock was down -$0.91, moving down -1.39 percent to $64.56. The average number of shares traded per day over the past five days has been 8,362,340 shares. 2 times new highs have been achieved over the past 5 days, with a -$1.14 fall in that time frame. In the last twenty days, the average volume was 8,769,265, while in the previous 50 days, it was 7,976,284.

Since last month, BMY stock retreated -5.09%. Shares of the company fell to $63.98 on 05/25/23, the lowest level in the past month. A 52-week high of $81.43 was reached on 02/06/23 after having rallying from a 52-week low of $65.14. Since the beginning of this year, BMY’s stock price has dropped by -10.27% or -$7.39, and marked a new high 9 times. However, the stock has declined by -20.72% since its 52-week high.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


BMY stock investors should be aware that Bristol-Myers Squibb Company (BMY) stock had its last reported insider trading activity 23 days ago on May 03. VESSEY RUPERT, the EVP & President, Research of the company, disposed of 50,385 shares for $67.06 on May 03. It resulted in a $3,378,818 divestment by the insider. Caforio Giovanni sold 240,000 shares at an average price of $74.65 on Feb 06. The insider now owns 236,104 shares following the transaction. On Feb 06, EVP, Chief Human Resources Powell Ann sold 11,183 shares at $74.69 apiece. The transaction was valued at $835,258.

Valuation Metrics

Right now, Bristol-Myers Squibb Company (BMY) has a P/E ratio of about 18.81. The stock’s beta is 0.43. Besides these, the trailing price-to-sales (P/S) ratio of 2.95, the price-to-book (PB) ratio of 4.26, and the price-to-cash flow ratio of 21.03 may also be considered.

The latest dividend of $0.57 per share was paid out, remained unchanged from last year’s $0.57. On Thursday December 8 2022, a $0.03 dividend increase was announced.

Financial Health

In the three months ended March 30, Bristol-Myers Squibb Company’s quick ratio stood at 1.30, while its current ratio was 1.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 1.10, and the total debt-to-equity ratio was 1.19. On the profitability front, the trailing twelve-month gross margin is 77.80% percent. In the year ended March 30, EBITDA margin amounted to 42.37%, whereas operating margins totaled 22.70%. Based on annual data, BMY earned $36.02 billion in gross profit and brought in $46.16 billion in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 11.80%. Return on equity (ROE) for the past 12 months was 22.80%.

In Bristol-Myers Squibb Company’s quarter-end financial report for March 30, it reported total debt of $35.08 billion against cash and short-term investments of $274.0 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. BMY’s revenue fell -2.74% to $11.41 billion during the quarter, while net income inched up to $11.34 billion. While analysts expected Bristol-Myers Squibb Company to report $1.97 quarterly earnings, the actual figure was $2.05 per share, beating the consensus estimate by 4.10%. During the quarter, the company generated $5.2 billion in EBITDA. The liabilities of Bristol-Myers Squibb Company were 62.4 billion at the end of its most recent quarter ended March 30, and its total debt was $39.39 billion. The value of shareholders’ equity is $2.1 billion.

Technical Picture

This quick technical analysis looks at Bristol-Myers Squibb Company’s (BMY) price momentum. With a historical volatility rate of 13.89%, the RSI 9-day stood at 28.72% on 25 May.

With respect to its five-day moving average, the current Bristol-Myers Squibb Company price is down by -1.74% percent or -$1.14. At present, BMY shares trade -4.51% below its 20-day simple moving average and -10.27% percent below its 100-day simple moving average. However, the stock is currently trading approximately -4.33% below its SMA50 and -13.87% below its SMA200.

Stochastic coefficient K was 18.25% and Stochastic coefficient D was 20.44%, while ATR was 1.25. Given the Stochastic reading of 11.33% for the 14-day period, the RSI (14) reading has been calculated as 33.28%. As of today, the MACD Oscillator reading stands at -0.66, while the 14-day reading stands at -1.46.

Analyst Ratings

Bristol-Myers Squibb Company (BMY) has been rated Overweight by analysts. According to 1 brokerage firm, BMY is a sell, and 12 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Bristol-Myers Squibb Company stock as buy, with 10 recommending it as overweight.

With a median target price of $81.00, the current consensus forecast for the stock is $59.00 – $92.00. Based on these forecasts, analysts predict Bristol-Myers Squibb Company (BMY) will achieve an average price target of $79.79.


Please enter your comment!
Please enter your name here